Skip to main content

MRK

Stock
Health Care
Drug Manufacturers - General

Performance overview

MRK Price
Price Chart

Forward-looking statistics

Beta
0.33
Risk
27.86%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees70K
Market cap$331.0B

Fundamentals

Enterprise value$224.5B
Revenue$63.9B
Revenue per employee—
Profit margin27.27%
Debt to equity71.99

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$6.88
Dividend per share$3.24
Revenue per share$25.27
Avg trading volume (30 day)$1B
Avg trading volume (10 day)$2B
Put-call ratio—

Macro factor sensitivity

Growth+1.0
Credit+0.7
Liquidity+0.1
Inflation-0.9
Commodities+0.1
Interest Rates-0.3

Valuation

Dividend yield4.00%
PEG Ratio8.61
Price to sales3.18
P/E Ratio8.61
Enterprise Value to Revenue3.51
Price to book4.21

Upcoming events

Next earnings dayFebruary 3, 2026
Next dividend day—
Ex. dividend dayJune 16, 2025

News

Merck (MRK) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Merck (MRK) stood at $79.96, denoting a -1.91% move from the preceding trading day.

Zacks Investment Research (July 18, 2025)
Are Investors Undervaluing Newmark Group (NMRK) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 18, 2025)
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?

MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.

Zacks Investment Research (July 11, 2025)
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap

Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD drug manufacturer Verona Pharma for $10 billion, adding yet another potential blockbuster to its expanding collection of post-Keytruda assets.

Forbes (July 11, 2025)
Merck to Buy Verona Pharma for Around $10 Billion

Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.

Bloomberg Markets and Finance (July 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free